Alkermes
first in human study underway and clinical strategy focused on early validation of biology | Alkermes
Company
Deck Type
Sector
Industry
Deck date
January 2022
Slide
31 of 36
Related slides by other companies
MindMed
Investor Presentation
June 2023
phase study results key phase study results support progression of results from phase progression of clinical trial demonstrate tolerability and support linear maintained across the tested doses and clinical effects align with potent regimen suitable regimen in withdrawal aligns with preclinical evidence offers potential to be a more frequencies engagement | MindMed
Boundless Bio
IPO
March 2024
spyglass reveals cancer targets both novel and validated that intersect distinct nodes of | Boundless Bio
Exscientia
Investor Presentation
August 2023
why are our clinical candidates different | Exscientia
Equillium
Investor Presentation
December 2023
phase study of in adults with moderate to severe target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io